| CORP. FOCUS |
Over the past 50 years, the pharmaceutical industry has concentrated on about 500 gene targets. The Human Genome Project has opened the field to an estimated 80 to 100,000 new gene products. The race is on to determine the role of these genes and their encoded proteins in disease phenotypes. However, the typical drug discovery process still requires, on average, 10 years and $500 million, according to the Pharmaceutical Research and Manufacturers of America. This huge investment has driven pharmaceutical companies to find more efficient technologies for drug discovery and development. Fluidigm Corporation provides a unique solution through fluidics at the nano-scale, using palm-sized devices with integrated channels and valves. Our vision is to combine our proprietary IFCs and gold-standard chemistries and analytical software and hardware into automated systems for protein crystallization and other life-science applications. These systems will enable life-science researchers in academia and industry to achieve mission critical goals with unrivaled efficiency |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |